产品管线

产品管线

安博生物在其产品管线中的各个

开发阶段拥有大量与众不同的候选产品,

专注于研发一流的生物制药产品机会。

我们还在各个开发阶段与多种资产

建立了许多尚未披露的合作伙伴关系。


DEVELOPMENT PIPELINE
Stage Product Partner
     
ARX788 αHER2 ADC – HER2+Breast Cancer(1)
ARX517 PSMA ADC - Oncology(2)
CD70 ADC - Oncology(3)
Bi-specific Anti-CD3 X Folate(4)
ARX618 PEG-FGF21 – NASH
ARX720 Relaxin – Heart Failure
Imrestor - Mastitis in Cattle(7)
ADCs – Oncology
Multi-Specific ADCs(9)

(1) Ambrx owns the worldwide rights to ARX788, with the exception of the People's Republic Of China, for which the rights to ARX788 have been licensed to Zhejiang Medicine Co., Ltd.

(2) Potential indications include prostate cancer and glioblastoma multiforme.

(3) Potential indications include renal cell carcinoma and nasopharyngeal carcinoma.

(4) Potential indications include ovarian cancer. Ambrx owns the wordwide rights to this product candidate, with the exception of the, People's Republic Of China, for which the rights have been licensed to a collaborator.

(8) Potential indications include oncology and autoimune/inflamatory diseases.



Key Description
Marketed
Phase 2
Phase 1
Preclinical
Discovery
Discovery Preclinical Phase 1 Phase 2 Phase 3 Marketed
 
Ambrx ADC and Bi-Specific Product Candidates
Bi-specific Anti-CD3 X Folate(4)
Collaboration Product and Product Candidates
ARX618 PEG-FGF21 – NASH
ARX720 Relaxin – Heart Failure
Imrestor - Mastitis in Cattle(6)
Other Early-Stage Programs
Multi-Specific ADCs(8)

(1) Ambrx owns the worldwide rights to ARX788, with the exception of the People's Republic Of China, for which the rights to ARX788 have been licensed to Zhejiang Medicine Co., Ltd.

(2) Potential indications include prostate cancer and glioblastoma multiforme.

(3) Potential indications include renal cell carcinoma and nasopharyngeal carcinoma.

(4) Potential indications include ovarian cancer. Ambrx owns the wordwide rights to this product candidate, with the exception of the, People's Republic Of China, for which the rights have been licensed to a collaborator.

(6) Under this collaboration, Elanco Animal Health, a division of Eli Lilly & CO., has multiple projects directed at metabolic, infectious and inflamatory diseases in livestock and companion animals in early-stage clinical development, but we do not expect any of these other product candidates to launch before 2017.

(8) Potential indications include hematologic and solid tumor cancers.